CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

X. Zhang,J. Zhou,D.D. Zhu,J Huang,J.H. Sun,T. F. Li,C.-S. Shi,Z.-C. Sun,Q.M. Hou,Z.-Y. Peng,W. Q. Yu,J.-S. Ji,W. J. Gu,G. H. Zhou,X. X. Xie,X.-H. Guo,G. H. Cao,Z.-H. Yu,H.H. Xu,J. Fang,S. H. Ying,W.-H. Hu,W.-B. Ji,J. Han,X. Wu,J. P. Zheng,J. Luo,Y.T. Chen,T Y Hu,L Li,H.J Hu,H.J. Du,Guoliang Shao

CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study

2019

Purpose To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

Keywords:

General surgery
Drug
Medicine
Liver cancer
Adverse effect
drug eluting beads
Internal medicine
overall survival
complete response
Gastroenterology
Bile acid
liver function
Prospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations